Vector Oncology is a leader in the design and delivery of care based Health Economics and Outcomes Research (HEOR) and data analytics in oncology. Headquartered in Memphis, Vector Oncology utilizes its comprehensive Oncology Data Warehouse and proprietary Patient Care Monitor patient engagement and outcomes platform to design deliver high quality projects generating real world evidence and insight. Prior to the transaction, the Contract Research Organization(CRO) business unit was also wholly owned by the Company.

George Clinical is a leading Asia-Pacific based clinical research organization with global capabilities differentiated by scientific leadership and extensive site networks. Headquartered in Australia, George Clinical has a staff operating in 11 countries, and provides the full range of clinical trial services to pharmaceutical, medical device and biotech customers for all trial phases, registration and post-marketing trials. George Clinical’s parent organization, The George Institute for Global Health, is a leader in chronic disease research with a global network of experts with whom George Clinical engages.

The sale transaction provides Vector Oncology’s CRO with the ability to accelerate its international growth in oncology and to expand to other therapeutic areas. The acquisition enables George Clinical to expand its robust operational expertise and scientific leadership in vascular, renal and respiratory diseases, neurology and endocrinology throughout the United States.

Cypress Associates LLC acted as financial advisor to Vector Oncology in the sale of its CRO division to George Clinical.